Results 11 to 20 of about 1,576,668 (338)
IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review [PDF]
Modern Rheumatology, 2019 Tocilizumab (TCZ) is an interleukin-6 (IL-6) inhibitor used for the treatment of rheumatoid arthritis (RA). It was developed in 2008, and its effectiveness is supported by evidence from all over the world based on its first decade of use. Although the overall efficacy and safety profiles of TCZ are similar to those of tumor necrosis factor (TNF ...
Atsushi Ogata +3 more
openaire +3 more sources
SIADH in Systemic JIA Resolving After Treatment With an IL-6 Inhibitor [PDF]
Pediatrics, 2018 Interleukin-6 (IL-6) is implicated in the pathogenesis of both systemic juvenile idiopathic arthritis (SJIA) and syndrome of inappropriate secretion of antidiuretic hormone (SIADH), but the 2 have not been previously described as occurring together.
Juanita K, Hodax +2 more
openaire +3 more sources
Pharmacological Research, 2019 Interleukin 6 (IL-6) is a pleiotropic cytokine that plays a role in the neuroendocrine system, insulin resistance, lipid metabolism, vascular disease, mitochondrial activities, neuropsychological behaviour, and also mediates communications between the immune and central nervous system (CNS).
Atzeni, Fabiola +4 more
openaire +4 more sources
Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome. [PDF]
Int J Med Sci, 2021 Cytokine release syndrome (CRS) may be the key factor in the pathology of severe coronavirus disease 2019 (COVID-19). As a major driver in triggering CRS in patients with COVID-19, interleukin-6 (IL-6) appears to be a promising target for therapeutics ...
Du P +5 more
europepmc +2 more sources
The Efficacy of IL-6 Inhibitor Tocilizumab in Reducing Severe COVID-19 Mortality: A Systematic Review [PDF]
PeerJ, 2020 Without proven, targeted therapies against SARS-CoV-2, it is crucial to counter the known pathophysiological causes of severe COVID-19, potentially utilizing existing drugs.
Kaye A, Siegel R.
europepmc +3 more sources
Particle and Fibre Toxicology, 2018 Background Epidemiological studies have shown that ambient air pollution is closely associated with increased respiratory inflammation and decreased lung function.
Chen-Wei Liu +11 more
doaj +2 more sources
A novel small-molecule inhibitor targeting the IL-6 receptor β subunit, glycoprotein 130
Journal of Immunology, 2015 IL-6 is a major causative factor of inflammatory disease. Although IL-6 and its signaling pathways are promising targets, orally available small-molecule drugs specific for IL-6 have not been developed.
K Y Park +16 more
core +2 more sources
Mit IL-6-Inhibitor gegen COVID-19
MMW - Fortschritte der Medizin, 2020 Red.
semanticscholar +3 more sources
Mediators of Inflammation, 2022 Background and Aim. Interleukin-6 (IL-6) modulates neurons–glia crosstalk and subsequently triggers hyperalgesia. This study is aimed at investigating whether the interaction between protein kinase C epsilon (PKCε) and signal transducer and activator of ...
Xiongjuan Li +15 more
doaj +1 more source
Virtual Screening of IL-6 Inhibitors for Idiopathic Arthritis [PDF]
Bioinformation, 2019 Juvenile idiopathic arthritis (JIA) is a heterogeneous disease characterized by the arthritis of unknown origin and IL6 is a known target for JIA. 20 known inhibitors towards IL-6 were screened and Methotrexate (MTX) having PubChem ID: 126941 showed high binding capacity with the receptor IL-6.
Shukla, Palak +5 more
openaire +2 more sources